Applied StemCell vs Cedars-Sinai Biomanufacturing: CDMO Comparison

Side-by-side comparison of Applied StemCell and Cedars-Sinai Biomanufacturing on independent FDA inspections, EMA and MHRA GMP certificates, clinical-program activity, and CDMO Signal Score. Data sourced from FDA, EMA EudraGMDP, MHRA GMDP, and ClinicalTrials.gov.

Milpitas, CA
Signal Score
60/100
Quality (FDA + GMP)
FDA inspections
0
FDA warning letters
0
EMA GMP certificates (active)
0
MHRA GMP certificates (compliant)
0
Clinical programs (matched)
0
Capacity
Modalities
Cell Therapy, Gene Editing
Los Angeles, CA
Signal Score
79/100
Quality (FDA + GMP)
100/100
FDA inspections
1
— NAI / VAI / OAI
1 / 0 / 0
FDA warning letters
0
EMA GMP certificates (active)
0
MHRA GMP certificates (compliant)
0
Clinical programs (matched)
31
Capacity
Modalities
Cell Therapy, Gene Editing

Key differences

  • Cedars-Sinai Biomanufacturing has FDA inspections on record (1); Applied StemCell does not yet appear in the FDA inspection database.
  • Both maintain clean enforcement records — no FDA OAI classifications or warning letters on file for either CDMO.
  • Cedars-Sinai Biomanufacturing appears as a manufacturing partner on more matched clinical programs (31 vs 0) — a broader sponsor book.
  • Composite Signal Score: Cedars-Sinai Biomanufacturing 79/100 vs Applied StemCell 60/100 — a 18-point gap reflecting the combined quality, capacity and financial signal.

On a 13-modality CDMO landscape, both Applied StemCell and Cedars-Sinai Biomanufacturing qualify as Cell Therapy manufacturers; Cedars-Sinai Biomanufacturing carries the higher composite Signal Score for Cell Therapy programs in this comparison.

What to evaluate for Cell Therapy programs

Both Applied StemCell and Cedars-Sinai Biomanufacturing qualify as Cell Therapy CDMOs. When choosing between them for Cell Therapy programs, weigh these four dimensions specifically — each carries through to the side-by-side scorecard above.

Autologous vs allogeneic

Autologous needs per-patient scheduling, chain-of-identity, and short turnaround; allogeneic needs scalable batch processing and a master cell bank strategy. Pick a CDMO proven in your model.

Vector & raw materials

Most cell therapies need a viral vector. Confirm whether the CDMO makes vector in-house or coordinates an external supplier, and how that affects timelines.

Closed-system & cleanrooms

Closed, automated processing reduces contamination risk and labor. Ask about cleanroom grade, automation platforms, and parallel-suite capacity.

Cold chain & logistics

Cryopreservation and chain-of-custody are critical for living cells. Evaluate the CDMO's cold-chain and apheresis-to-infusion logistics.

See all Cell Therapy CDMOs ranked by Signal Score →

Frequently asked: Applied StemCell vs Cedars-Sinai Biomanufacturing

Which has the stronger FDA inspection record, Applied StemCell or Cedars-Sinai Biomanufacturing?

Both Applied StemCell and Cedars-Sinai Biomanufacturing maintain clean enforcement records on file — no FDA warning letters and no OAI classifications. Applied StemCell has 0 FDA inspections on record; Cedars-Sinai Biomanufacturing has 1.

Which is more active in clinical-stage manufacturing — Applied StemCell or Cedars-Sinai Biomanufacturing?

Applied StemCell is matched to 0 ClinicalTrials.gov records as a manufacturing partner; Cedars-Sinai Biomanufacturing is matched to 31. Higher counts indicate broader sponsor exposure but say nothing about approved-product track record — pair this number with each CDMO's profile page for context.

Which is better for Cell Therapy manufacturing — Applied StemCell or Cedars-Sinai Biomanufacturing?

Both Applied StemCell and Cedars-Sinai Biomanufacturing are tagged as Cell Therapy CDMOs in our directory, so both are credible options for Cell Therapy programs. The most important differentiator for Cell Therapy selection is typically autologous vs allogeneic: Autologous needs per-patient scheduling, chain-of-identity, and short turnaround; allogeneic needs scalable batch processing and a master cell bank strategy. Pick a CDMO proven in your model. Review each CDMO's profile and inspection record before shortlisting.

What does the Signal Score gap mean in practice?

Applied StemCell carries a Signal Score of 60/100 and Cedars-Sinai Biomanufacturing carries 79/100 — a meaningful lead for Cedars-Sinai Biomanufacturing. The Signal Score combines quality (FDA inspections + EMA/MHRA GMP), operational performance, financial stability, and capacity intelligence. CDMOs cannot pay to influence their score.

Evaluating Applied StemCell and Cedars-Sinai Biomanufacturing for a program?

Use the free AI matchmaker to weigh both against your specific requirements — capacity, modality, regulatory record, geography — and surface other qualified options.

Find & compare CDMOs →
Sourced from FDA, EMA EudraGMDP, MHRA GMDP, and ClinicalTrials.gov.